Dupixent
Prescription
Biologic (IL-4/IL-13 Inhibitor)
Dupilumab Injection
Manufacturer: Sanofi / Regeneron
Description
Dupixent is the first biologic approved specifically for moderate-to-severe atopic dermatitis. Dupilumab is a fully human monoclonal antibody that inhibits IL-4 and IL-13 signalling — the key type 2 inflammatory cytokines driving eczema. A breakthrough for patients with severe, refractory eczema.
Active Compounds
No tracked compounds
Indications
- Moderate-to-severe atopic dermatitis
- Asthma (moderate-to-severe eosinophilic)
- Chronic rhinosinusitis with nasal polyps
- Prurigo nodularis
Dosage
600mg subcutaneous loading dose, then 300mg every 2 weeks.
Formulations
Full Ingredient List
- Dupilumab
- L-Histidine
- L-Histidine Hydrochloride Monohydrate
- L-Arginine Hydrochloride
- Sodium Acetate Trihydrate
- Acetic Acid
- Sucrose
- Polysorbate 80
- Water for Injection
Side Effects
- Injection site reactions
- Conjunctivitis and keratitis (unique to dupilumab)
- Oral herpes
- Eosinophilia (transient)
- Arthralgia
Warnings
- Monitor for eye symptoms (conjunctivitis is common)
- Do not discontinue systemic corticosteroids abruptly when starting
- No mandatory blood monitoring required (advantage)
- Do not use with live vaccines
- Very expensive — limited access in India